Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Travere Therapeutics FILSPARI New Drug Application For Type 1 – New Molecular Entity Was Approved On 02/17/2023

Travere Therapeutics FILSPARI New Drug Application For Type 1 – New Molecular Entity Was Approved On 02/17/2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216403

byHappy Mohamed

February 17, 2023

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216403

C21 Investments FY23 Net Income Drops 97%, What About Adjusted EBITDA?

By Vuk Zdinjak

June 14, 10:11 AM

C21 Investments Inc. (OTCQX: CXXIF) (CSE:CXXI) released its audited financial statements for its fiscal year ended January 31, 2023, revealing revenue of $28.9 million – down 12% compared to $33 million in FY 2022.

CSE:CXXI

Elon Musk Highlights ChatGPT’s Hallucinations, But Not Everyone Is Convinced

By Ananya Gairola

July 11, 9:54 PM

Elon Musk's comments on chatGPT's hallucinations have ignited a debate on the accuracy and reliability of AI language models, with netizens expressing different viewpoints on the matter.

GOOG